Brice Ozenne

List of Publications by Year
in descending order

56 papers	1,816 citations	394421 19 h-index	315739 38 g-index
62 all docs	62 docs citations	62 times ranked	2602 citing authors

#	ARTICLE	IF	CITATIONS
1	A High-Resolution *In Vivo* Atlas of the Human Brain's Serotonin System. Journal of Neuroscience, 2017, 37, 120-128.	3.6	262
2	Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology, 2019, 44, 1328-1334.	5.4	259
3	The precision–recall curve overcame the optimism of the receiver operating characteristic curve in rare diseases. Journal of Clinical Epidemiology, 2015, 68, 855-859.	5.0	209
4	A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. International Journal of Molecular Sciences, 2021, 22, 835.	4.1	96
5	A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. European Neuropsychopharmacology, 2020, 33, 71-80.	0.7	88
6	Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study. European Heart Journal, 2016, 38, ehw496.	2.2	74
7	riskRegression: Predicting the Risk of an Event using Cox Regression Models. R Journal, 2017, 9, 440.	1.8	64
8	Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. European Neuropsychopharmacology, 2021, 50, 121-132.	0.7	57
9	The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials. JAMA Oncology, 2016, 2, 901.	7.1	47
10	An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring. Statistical Methods in Medical Research, 2018, 27, 1230-1239.	1.5	43
11	On the estimation of average treatment effects with right–censored time to event outcome and competing risks. Biometrical Journal, 2020, 62, 751-763.	1.0	42
12	Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. Journal of Psychopharmacology, 2021, 35, 459-468.	4.0	40
13	Pre-intervention test-retest reliability of EEG and ERP over four recording intervals. International Journal of Psychophysiology, 2018, 134, 30-43.	1.0	37
14	Very Low Cerebral Blood Volume Predicts Parenchymal Hematoma in Acute Ischemic Stroke. Stroke, 2013, 44, 2318-2320.	2.0	33
15	Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol. Frontiers in Psychiatry, 2020, 11, 641.	2.6	30
16	Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer's disease in hypertension. Brain, 2023, 146, 1141-1151.	7.6	30
17	Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report. Frontiers in Pharmacology, 2022, 13, 841648.	3.5	29
18	Resumption of oral anticoagulation following traumatic injury and risk of stroke and bleeding in patients with atrial fibrillation: a nationwide cohort study. European Heart Journal, 2018, 39, 1698-1705a.	2.2	28

#	Article	IF	Citations
19	An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget, 2016, 7, 82953-82960.	1.8	22
20	Evaluation of inferential methods for the net benefit and win ratio statistics. Journal of Biopharmaceutical Statistics, 2020, 30, 765-782.	0.8	20
21	Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels. Human Brain Mapping, 2020, 41, 4518-4528.	3.6	19
22	Effects of a single dose of psilocybin on behaviour, brain 5-HT2A receptor occupancy and gene expression in the pig. European Neuropsychopharmacology, 2021, 42, 1-11.	0.7	19
23	Safety and EEG data quality of concurrent high-density EEG and high-speed fMRI at 3 Tesla. PLoS ONE, 2017, 12, e0178409.	2.5	18
24	Pretreatment qEEG biomarkers for predicting pharmacological treatment outcome in major depressive disorder: Independent validation from the NeuroPharm study. European Neuropsychopharmacology, 2021, 49, 101-112.	0.7	18
25	The structure of the serotonin system: A PET imaging study. NeuroImage, 2020, 205, 116240.	4.2	17
26	Verbal learning and memory outcome in selective amygdalohippocampectomy versus temporal lobe resection in patients with hippocampal sclerosis. Epilepsy and Behavior, 2018, 79, 180-187.	1.7	14
27	Brain serotonin 4 receptor binding is inversely associated withÂverbal memory recall. Brain and Behavior, 2017, 7, e00674.	2.2	13
28	Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit. Journal of the National Cancer Institute, 2019, 111, 1186-1191.	6.3	13
29	Season-independent cognitive deficits in seasonal affective disorder and their relation to depressive symptoms. Psychiatry Research, 2017, 257, 219-226.	3.3	12
30	Default mode network functional connectivity negatively associated with trait openness to experience. Social Cognitive and Affective Neuroscience, 2021, 16, 950-961.	3.0	12
31	NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD. Journal of Psychiatric Research, 2021, 141, 57-65.	3.1	12
32	Emotional faces processing in major depressive disorder and prediction of antidepressant treatment response: A NeuroPharm study. Journal of Psychopharmacology, 2022, 36, 626-636.	4.0	11
33	Reward processing in major depressive disorder and prediction of treatment response â€" Neuropharm study. European Neuropsychopharmacology, 2021, 44, 23-33.	0.7	10
34	Stress-Hormone Dynamics and Working Memory in Healthy Women Who Use Oral Contraceptives Versus Non-Users. Frontiers in Endocrinology, 2021, 12, 731994.	3.5	9
35	A High-Resolution In Vivo Atlas of the Human Brain's Serotonin System. Journal of Neuroscience, 2017, 37, 120-128.	3.6	8
36	Amygdala response to emotional faces in seasonal affective disorder. Journal of Affective Disorders, 2018, 229, 288-295.	4.1	8

#	ARTICLE	IF	CITATIONS
37	Spatially regularized mixture model for lesion segmentation with application to stroke patients. Biostatistics, 2015, 16, 580-595.	1.5	7
38	Visual stimuli induce serotonin release in occipital cortex: A simultaneous positron emission tomography/magnetic resonance imaging study. Human Brain Mapping, 2020, 41, 4753-4763.	3.6	7
39	Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 study. Translational Psychiatry, 2022, 12, .	4.8	7
40	Psychometric Properties of the Verbal Affective Memory Test-26 and Evaluation of Affective Biases in Major Depressive Disorder. Frontiers in Psychology, 2020, 11, 961.	2.1	6
41	Comparison of classification methods for tissue outcome after ischaemic stroke. European Journal of Neuroscience, 2019, 50, 3590-3598.	2.6	5
42	Small sample corrections for Wald tests in latent variable models. Journal of the Royal Statistical Society Series C: Applied Statistics, 2020, 69, 841-861.	1.0	5
43	Net benefit in the presence of correlated prioritized outcomes using generalized pairwise comparisons: A simulation study. Statistics in Medicine, 2021, 40, 553-565.	1.6	5
44	The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study. Frontiers in Endocrinology, 2022, 13, 799675.	3.5	5
45	Self-perceived personality characteristics in seasonal affective disorder and their implications for severity of depression. Psychiatry Research, 2018, 262, 108-114.	3.3	4
46	A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons. Biometrical Journal, 2021, 63, 272-288.	1.0	4
47	The asymptotic distribution of the Net Benefit estimator in presence of right-censoring. Statistical Methods in Medical Research, 2021, 30, 2399-2412.	1.5	4
48	Correcting the bias of the net benefit estimator due to right‑censored observations. Biometrical Journal, 2021, 63, 893-906.	1.0	3
49	Brain serotonin transporter is associated with cognitive‑affective biases in healthy individuals. Human Brain Mapping, 0, , .	3.6	3
50	Evaluation of Early Reperfusion Criteria in Acute Ischemic Stroke. Journal of Neuroimaging, 2015, 25, 952-958.	2.0	2
51	Efficient Estimation in the Fine and Gray Model. Journal of the American Statistical Association, 2023, 118, 2482-2490.	3.1	2
52	Controlling the familywise error rate when performing multiple comparisons in a linear latent variable model. Computational Statistics, 2023, 38, 1-23.	1.5	2
53	Severity of self-reported depressive symptoms in a healthy sample is modulated by trait Harm Avoidance, not by 5-HTTLPR polymorphism. Psychiatry Research, 2020, 291, 113029.	3.3	1
54	Preprocessing, Prediction and Significance: Framework and Application to Brain Imaging. Lecture Notes in Computer Science, 2019, , 196-204.	1.3	1

#	Article	IF	Citations
55	Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial. BMJ Open, 2021, 11, e052922.	1.9	1
56	Individualized quantification of the benefit from reperfusion therapy using stroke predictive models. European Journal of Neuroscience, 2019, 50, 3251-3260.	2.6	0